Viking Therapeutics (VKTX) Rebounds on Bargain-Hunting. Are You Missing Out?

We recently published 10 Big Names With Surprising Gains. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Wednesday’s best performers.

Viking Therapeutics bounced back by 5.46 percent on Wednesday to finish at $25.69 apiece as investors resorted to early bargain-hunting to take advantage of its cheap valuations.

This followed the company’s 42-percent decline on Tuesday, dragged by results of its weight loss clinical trial that saw a huge dropout rate in the number of enrollees due to mild to moderate adverse effects, including nausea and vomiting.

Viking Therapeutics (VKTX) Rebounds on Bargain-Hunting. Are You Missing Out?

In a statement, Viking Therapeutics, Inc. (NASDAQ:VKTX) said it registered a 28-percent dropout rate in the overall number of enrollees for the second phase of its VK2735 clinical study, sparking concerns about the drug’s tolerability.

In a call with analysts, Viking Therapeutics, Inc. (NASDAQ:VKTX) CEO Brian Lian said that GI-related adverse event rates might be further reduced through lower starting doses and or slower dose escalation.

He added that the company was looking to explore it further in an upcoming maintenance dosing study.

Following the resu

While we acknowledge the risk and potential of VKTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VKTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.